Eric B. Haura
机构：Moffitt Cancer Center · ORCID：0000-0003-3114-1909
发表论文 1000 篇 · 总被引 25631 次 · h-index 80
代表论文
- Abstract CT021: Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC) (2026 · Cancer Research · 被引 2)
- Integrating molecular dynamics and machine learning to identify potential apo-state conformational and solvent-exposure signatures associated with resistant KRAS mutants (2026 · Frontiers in Chemical Biology)
- Ex Vivo Culture of Patient-Derived Primary, Metastatic, and Post-Mortem Lung Cancer Reveals Targetable States of EMT and Metabolic Plasticity (2026 · bioRxiv (Cold Spring Harbor Laboratory))
- Data from Targeting GSTZ1 Sensitizes <i>KRAS</i><i><sup>G12C</sup></i>-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring (2026)
- Figure 4 from Targeting GSTZ1 Sensitizes <i>KRAS</i><i><sup>G12C</sup></i>-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring (2026)
- Figure 6 from Targeting GSTZ1 Sensitizes <i>KRAS</i><i><sup>G12C</sup></i>-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring (2026)